Gilead Sciences (GILD): NASDAQ:GILD
We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at...
Reasons for bullish bias:
- Bounce from strong support
- Bullish engulfing candle formed at weekly closing
Entry Level(CMP): 75.58
Stop Loss Level: 71.20
Take Profit Level 1: 79.96
Take Profit Level 2: 84.34
Take Profit Level 3: Open
If you haven`t bought GILD before the previous earnings:
Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 80usd strike price Calls with
an expiration date of 2024-6-21,
for a premium of approximately $3.10.
If these options prove to be profitable prior to the...
In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival...
GILD is pushing a 6-year resistance line. It broke through for a few days a year ago before being battered back down. Let's see if it'll make the move stick this time.
In the biotechnology sector, the differing financial metrics and market positions of Amgen Inc. (AMGN) and Gilead Sciences Inc. (GILD) present an interesting case for investors. It could be strategic to consider buying AMGN while contemplating selling GILD based on their respective financial performances and market dynamics.
Reasons to Prefer AMGN Over GILD:
...
As you can see on the presented chart first goes Gilead Sciences, USA Pharmaceutical Giant which we see as the main sorce of income and R&D of USA Pharmaceuticals Industry. Main levels are 82.50, 79.00, 73.50, 69.00. Second is Pfizer, Europe Pharmaceutical giant, main levels are 54.50, 46.50, 28.50. Third is Merck, based, again, in Europe, main levels are 115.00,...
If you haven`t bought GILD on the Remdesivir approval:
Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 80usd strike price in the money Calls with
an expiration date of 2024-1-19,
for a premium of approximately $4.25.
If these options prove to be profitable...
This trade has multiple patterns on M15, and it is with the trend. All timeframes are overbought and have divergence, this trade should be able to fall to the bottom and maybe even more as it is hitting the H4 moving average and has the strength to fall especially with the news regarding Isreal as of now.
After an A-B-C Corrective Wave (red coloured wave), GILD is forming a 1-2-3-4-5 Motive Wave (green coloured wave). Presently, 4th corrective wave (yellow coloured wave) of this Motive Wave is under progress.
4th wave can be a triangle (3-3-3-3-3) as is the case here. Within this triangle, each of the five waves has a three wave pattern.
There is a gap below...
GILD has formed a bullish flag and price is above 20/50/100/200 EMAs. If resistance of 80 is broken, price will also go above upper trend line. First resistance likely at 84 after breakout and then at 91.
this stock has a history of breaking multiple SMA resistance which is usually bullish, but it always climbs back below and heads lower after that breakout.
I think longs should be very cautious, short term pump to 83 is possible, we dump after in my opinion though. boost and follow for more! 💛
A bullish flag seems to be in development in the NASDAQ:GILD chart. It's not still clear but it could see $102s as final target. Invalidation below $73.
The previous 2 alerts didn't cofirm the combo.
This last alert already created a new crossover and positive price action.
Let's see if it will work out as always.
The PEAD projected a bearish outlook for NASDAQ:GILD after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 72.73%.
XABCD, ABC patterns at play. Confirmation via eMA, candlestick pattern. Here we go.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is...
